Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
NCT ID NCT04923789
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how long patients live without their cancer getting worse. The trial enrolled 100 adults aged 18 to 65 and tracked outcomes like survival and side effects over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
autologous hematopoietic stem cell transplant followed by chimeric antigen receptor T (CAR-T) cell therapy
What this could lead to
If successful, this combination could offer a more effective treatment option for patients with hard-to-treat B-cell lymphoma that has come back or not responded to standard therapy.
What could go wrong
This is a single-center, non-randomized study with no control group, so results may not be generalizable. Both stem cell transplant and CAR-T therapy carry significant risks, including severe side effects like infection, organ damage, and immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China